Top

Cancer Chemotherapy and Pharmacology

Published in:

01-01-2016 | Original Article

Impact of dexrazoxane on doxorubicin-induced aneuploidy in somatic and germinal cells of male mice

Authors: S. M. Attia, S. F. Ahmad, S. A. Bakheet

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2016

Abstract

Purpose

Despite dexrazoxane’s increasing use in mitigating doxorubicin-induced cardiotoxicity, no data are available in the literature on the potential aneugenicity of drug combination. Therefore, detailed evaluation of aneugenic potential of this combination is essential to provide more insights into aneuploidy induction that may play a role in the development of secondary malignancies and reproductive toxicity after treatment with doxorubicin. Thus, our aim was to determine whether dexrazoxane has influence on the aneuploidy induced by doxorubicin in germinal and somatic cells of male mice.

Methods

Sperm BrdU-incorporation assay, sperm FISH assay and the bone marrow micronucleus test complemented by FISH assay were used to determine aneuoploidy. Moreover, the formation of 8-OHdG, one of the oxidative DNA damage by-products, has been evaluated.

Results

Dexrazoxane was not aneugenic at the doses tested. Pre-treatment of mice with dexrazoxane significantly reduced doxorubicin-induced aneuploidy in a dose-dependent manner. Doxorubicin induced marked biochemical alterations characteristic of oxidative DNA damage, and prior administration of dexrazoxane before doxorubicin challenge ameliorated this biochemical marker.

Conclusion

This study provides evidence that dexrazoxane has a protective role in the abatement of doxorubicin-induced aneuploidy. This activity resides, at least in part, in its radical scavenger activity. Thus, dexrazoxane can avert secondary malignancies and abnormal reproductive outcomes in cured cancer patients exposed to doxorubicin.

Hortobagyi GN (1997) Anthracyclines in the treatment of cancer. An overview. Drugs 54(Suppl 4):1–7PubMedCrossRef

Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57(7):727–741PubMedCrossRef

Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22(4):263–302PubMedCrossRef

Fritz B, Aslan M, Kalscheuer V, Ramsing M, Saar K, Fuchs B, Rehder H (2001) Low incidence of UPD in spontaneous abortions beyond the 5th gestational week. Eur J Hum Genet EJHG 9(12):910–916. doi:10.1038/sj.ejhg.5200741 PubMedCrossRef

Ganapathi R, Hoeltge G, Casey G, Grabowski D, Neelon R, Ford J (1996) Acquisition of doxorubicin resistance in human leukemia HL-60 cells is reproducibly associated with 7q21 chromosomal anomalies. Cancer Genet Cytogenet 86(2):116–119PubMedCrossRef

Aly MS, Othman OE, El Nahas SM (1999) Specific numerical chromosomal aberrations induced by adriamycin. Environ Mol Mutagen 33(2):161–166PubMedCrossRef

Theodore C, Bayle C, Bernheim A, Wibault P (2002) Secondary leukaemia after treating advanced bladder cancer with methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and radiotherapy. BJU Int 90(4):470–471PubMedCrossRef

Attia SM (2008) Mutagenicity of some topoisomerase II-interactive agents. Saudi Pharm J 16:1–24

Attia SM (2011) Comparative aneugenicity of doxorubicin and its derivative idarubicin using fluorescence in situ hybridization techniques. Mutat Res 715(1–2):79–87. doi:10.1016/j.mrfmmm.2011.07.012 PubMedCrossRef

10.

Buss JL, Hasinoff BB (1993) The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 40(1–2):86–95PubMedCrossRef

11.

van Dalen EC, Caron HN, Dickinson HO, Kremer LC (2005) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. doi:10.1002/14651858.CD003917.pub2 PubMed

12.

Pearlman M, Jendiroba D, Pagliaro L, Keyhani A, Liu B, Freireich EJ (2003) Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. Leuk Res 27(7):617–626PubMedCrossRef

13.

Jones RL (2008) Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther 6(10):1311–1317. doi:10.1586/14779072.6.10.1311 PubMedCrossRef

14.

Herman EH, Hasinoff BB, Zhang J, Raley LG, Zhang TM, Fukuda Y, Ferrans VJ (1995) Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicology 98(1–3):163–175PubMedCrossRef

15.

Hasinoff BB, Kala SV (1993) The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925. Agents Actions 39(1–2):72–81PubMedCrossRef

16.

Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM (1995) A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50(7):953–958PubMedCrossRef

17.

Conde-Estevez D, Mateu-de Antonio J (2014) Treatment of anthracycline extravasations using dexrazoxane. Clin Transl Oncol 16(1):11–17. doi:10.1007/s12094-013-1100-7 PubMedCrossRef

18.

Sen S (2000) Aneuploidy and cancer. Curr Opin Oncol 12(1):82–88PubMedCrossRef

19.

Bakheet SA, Attia SM, Al-Rasheed NM, Al-Harbi MM, Ashour AE, Korashy HM, Abd-Allah AR, Saquib Q, Al-Khedhairy AA, Musarrat J (2011) Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells. Mutagenesis 26(4):533–543. doi:10.1093/mutage/ger013 PubMedCrossRef

20.

Attia SM, Al-Anteet AA, Al-Rasheed NM, Alhaider AA, Al-Harbi MM (2009) Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane. Cancer Chemother Pharmacol 64(4):837–845. doi:10.1007/s00280-009-0934-8 PubMedCrossRef

21.

Schmid TE, Attia S, Baumgartner A, Nuesse M, Adler ID (2001) Effect of chemicals on the duration of male meiosis in mice detected with laser scanning cytometry. Mutagenesis 16(4):339–343PubMedCrossRef

22.

Attia SM, Schmid TE, Badary OA, Hamada FM, Adler ID (2002) Molecular cytogenetic analysis in mouse sperm of chemically induced aneuploidy: studies with topoisomerase II inhibitors. Mutat Res 520(1–2):1–13PubMedCrossRef

23.

Krishna G, Hayashi M (2000) In vivo rodent micronucleus assay: protocol, conduct and data interpretation. Mutat Res 455(1–2):155–166PubMedCrossRef

24.

Attia SM (2009) Use of centromeric and telomeric DNA probes in in situ hybridization for differentiation of micronuclei induced by lomefloxacin. Environ Mol Mutagen 50(5):394–403. doi:10.1002/em.20451 PubMedCrossRef

25.

Attia SM (2007) The genotoxic and cytotoxic effects of nicotine in the mouse bone marrow. Mutat Res 632(1–2):29–36. doi:10.1016/j.mrgentox.2007.04.010 PubMedCrossRef

26.

Attia SM, Kliesch U, Schriever-Schwemmer G, Badary OA, Hamada FM, Adler ID (2003) Etoposide and merbarone are clastogenic and aneugenic in the mouse bone marrow micronucleus test complemented by fluorescence in situ hybridization with the mouse minor satellite DNA probe. Environ Mol Mutagen 41(2):99–103. doi:10.1002/em.10135 PubMedCrossRef

27.

Attia SM (2012) Influence of resveratrol on oxidative damage in genomic DNA and apoptosis induced by cisplatin. Mutat Res 741(1–2):22–31. doi:10.1016/j.mrgentox.2011.10.008 PubMedCrossRef

28.

Ling YH, El-Naggar AK, Priebe W, Perez-Soler R (1996) Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49(5):832–841PubMed

29.

Murray AW (1992) Creative blocks: cell-cycle checkpoints and feedback controls. Nature 359(6396):599–604. doi:10.1038/359599a0 PubMedCrossRef

30.

Adler ID (1993) Synopsis of the in vivo results obtained with the 10 known or suspected aneugens tested in the CEC collaborative study. Mutat Res 287(1):131–137PubMedCrossRef

31.

Pytel D, Wysocki T, Majsterek I (2006) Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance. Comp Biochem Physiol Toxicol Pharmacol CBP 144(1):85–92. doi:10.1016/j.cbpc.2006.06.010 CrossRef

32.

Martin RH, Rademaker AW, Leonard NJ (1995) Analysis of chromosomal abnormalities in human sperm after chemotherapy by karyotyping and fluorescence in situ hybridization (FISH). Cancer Genet Cytogenet 80(1):29–32PubMedCrossRef

33.

Dhawan A, Kayani MA, Parry JM, Parry E, Anderson D (2003) Aneugenic and clastogenic effects of doxorubicin in human lymphocytes. Mutagenesis 18(6):487–490PubMedCrossRef

34.

Hofland KF, Thougaard AV, Sehested M, Jensen PB (2005) Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin Cancer Res 11(10):3915–3924. doi:10.1158/1078-0432.CCR-04-2343 PubMedCrossRef

35.

Kaneko T, Tahara S, Matsuo M (1996) Non-linear accumulation of 8-hydroxy-2′-deoxyguanosine, a marker of oxidized DNA damage, during aging. Mutat Res 316(5–6):277–285PubMedCrossRef

36.

Floyd RA (1990) The role of 8-hydroxyguanine in carcinogenesis. Carcinogenesis 11(9):1447–1450PubMedCrossRef

37.

Valavanidis A, Vlachogianni T, Fiotakis C (2009) 8-hydroxy-2′ -deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health, Part C Environ Carcinog Ecotoxicol Rev 27(2):120–139. doi:10.1080/10590500902885684 CrossRef

38.

Grankvist K, Henriksson R (1987) Doxorubicin and epirubicin iron-induced generation of free radicals in vitro. A comparative study. Biosci Rep 7(8):653–658PubMedCrossRef

39.

Ravi D, Das KC (2004) Redox-cycling of anthracyclines by thioredoxin system: increased superoxide generation and DNA damage. Cancer Chemother Pharmacol 54(5):449–458. doi:10.1007/s00280-004-0833-y PubMedCrossRef

40.

Attia SM (2010) Deleterious effects of reactive metabolites. Oxid Med Cell Longev 3(4):238–253PubMedPubMedCentralCrossRef

41.

Junjing Z, Yan Z, Baolu Z (2010) Scavenging effects of dexrazoxane on free radicals. J Clin Biochem Nutr 47(3):238–245. doi:10.3164/jcbn.10-64 PubMedPubMedCentralCrossRef

42.

Galetta F, Franzoni F, Cervetti G, Regoli F, Fallahi P, Tocchini L, Carpi A, Antonelli A, Petrini M, Santoro G (2010) In vitro and in vivo study on the antioxidant activity of dexrazoxane. Biomed Pharmacother 64(4):259–263. doi:10.1016/j.biopha.2009.06.018 PubMedCrossRef

Title: Impact of dexrazoxane on doxorubicin-induced aneuploidy in somatic and germinal cells of male mice
Authors: S. M. Attia
S. F. Ahmad
S. A. Bakheet
Publication date: 01-01-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-015-2925-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2016

Cytotoxic drugs: past, present and future

Early metabolic change in 18F-FDG-PET by measuring the single largest lesion predicts chemotherapeutic effects and patients’ survival: PEACH study

Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer

A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site

A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin–docetaxel with or without trastuzumab in locally advanced breast cancer

Malformin A1 promotes cell death through induction of apoptosis, necrosis and autophagy in prostate cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer